TARIS

TARIS Biomedical is a biotechnology company founded in 2008, aiming to revolutionize treatments for challenging bladder conditions. With a tailored, extended-release system and minimally-invasive procedures, the company has garnered attention for its innovative therapies. TARIS Biomedical's unique system allows for continuous drug delivery in the bladder for extended periods, ranging from weeks to months. This solution can be deployed and retrieved through minimally-invasive, in-office procedures, allowing for customizable drug release to address the specific needs of each condition.

The company received a significant boost with a $25.00M Series B investment on 21 December 2017. The investors in this round included Polaris Partners, RA Capital Management, Flagship Pioneering, Yonghua, Millhouse, Roman Abramovich, and Bristol-Myers Squibb. This substantial investment underscores the confidence that renowned venture capital firms and industry players have in TARIS Biomedical's innovative approach and potential to make a meaningful impact in the biotechnology, healthcare, and pharmaceutical industries. With its focus on addressing unmet medical needs and improving patients' lives, TARIS Biomedical presents an exciting opportunity for investors seeking to support groundbreaking advancements in healthcare.